Xcout IntelSign inSubscribe

Evolus, Inc.

EOLSPharmaceuticalsNewport Beach, United States

Evolus, Inc. is a performance beauty enterprise that furnishes the United States market with medical aesthetic solutions for healthcare professionals and their patients. A key product in its portfolio is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. This product is specifically designed for adults seeking the temporary smoothing of moderate to severe glabellar (frown) lines. Founded in 2012, Evolus, Inc. maintains its corporate headquarters in Newport Beach, California.

Subscribe to see Evolus, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

Evolus, Inc. at a glance

Evolus, Inc. is a pharmaceuticals company headquartered in Newport Beach, United States. It is publicly listed (EOLS) with a market capitalisation of $487.5M. Xcout tracks 14 named people at Evolus, Inc., including David Moatazedi (President, Chief Executive Officer & Director).

Industry
Pharmaceuticals
Headquarters
Newport Beach, United States
Market cap
$487.5M
Employees
372
Ticker
EOLS

Evolus, Inc. leadership

  • David MoatazediPresident, Chief Executive Officer & Director
  • Tatjana MitchellChief Financial Officer
  • Rui Avelar C.CFP Dip.SportMedChief Medical Officer and Head of Research & Development
  • Jessica NovakSenior Vice President of Human Resources
  • Kurt KnabSenior Vice President of Sales
  • Nareg SagherianHead of Global Investor Relations & Corporate Communications

8 more named people on record for Evolus, Inc., with roles, board committees and tenure — see the full roster →

Evolus, Inc. competitors

A few of Evolus, Inc.'s closest competitors — see the full list of competitors and alternatives →

COSMO NV COSMO NV0RGI · PharmaceuticalsIreland
60% matchPublic

Cosmo N.V., a life sciences company, develops and manufactures pharmaceuticals and contracts for gastroenterology, dermatology, and health tech in Ireland and internationally. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Rifamycin, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Clascoterone, which is in phase-3 clinical trial for the treatment of male pattern hair loss. It is also developing novel UC treatment, which is in phase-2 clinical trial for the treatment of distal inflammatory bowel disease/distal ulcerative colitis/proctitis; BAD Treatment (CB-01-33), which is in phase-2 clinical trial for the treatment of colesevelam formulation/bile acid diarrhea; and CB-03-10, which is in phase-1 clinical trial for the treatment of oncology solid tumors, as well as provides Cosmo's AI technology, a GI Genius intelligent endoscopy system. The company was formerly known as Cosmo Pharmaceuticals N.V. and changed its name to Cosmo N.V. in April 2026. The company was founded in 1997 and is headquartered in Dublin, Ireland.

Market cap$1.3B
Employees324
COSMO NV COSMO NV competitors & alternatives →
Bausch Health Companies Inc.BHC · PharmaceuticalsLaval, Canada
60% matchPublic

Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.

Market cap$1.8B
Employees20,300
Bausch Health Companies Inc. competitors & alternatives →

Get Evolus, Inc.'s news by email

Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.

Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →

Share this card

Post the link and the card appears automatically — each network fetches the image itself.

Evolus, Inc. — share card preview

Instagram, TikTok and Slack canvases don't expand links — download the card as a PNG and post it as an image instead.

More on Evolus, Inc. in Xcout Intel

  • 14 named people with titles, LinkedIn and board committees
  • 2 corporate events with sources — deals, leadership changes, layoffs
  • The full competitor set, tracking, exports and API access
Subscribe to Xcout Intel →